Full-Time

Director/Senior Director

Regulatory CMC

Posted on 8/6/2024

Vor Bio

Vor Bio

51-200 employees

Develops targeted therapies for blood cancers

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Generous transportation stipend offered for commuting.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • PharmD or PhD preferred with ≥8 years of industry experience in Regulatory CMC biologics.
  • Experience working in cell therapies is preferred.
  • A strong scientific background and training in cell and tissue biology is a plus.
  • A strong background & track record in filing regulatory submissions from early development to pre and post approval submissions and product lifecycle management in the area of cell therapy/biologics.
  • A broad understanding of all aspects of CMC including process development, regulatory and quality requirements, analytical development, formulation and drug product technologies, distribution in US/ex-US.
  • Experience interfacing with FDA, and other regulatory agencies within the pharmaceutical industry.
  • Demonstrated risk identification and critical thinking skills.
  • Strong understanding of the global pharmaceutical drug development and regulatory environment, including anticipating future trends and opportunities in cell therapy.
  • Ability to interact effectively across all levels of the organizations; integrates functional expertise with business knowledge to solve problems, meet priorities and deadlines in alignment with corporate goals and objectives.
  • Recognized as an influential leader who possesses a cross-functional collaborative skill set.
  • Excellent oral and written communication skills with strong attention to detail and the ability to coordinate multiple activities in a faced paced biotech environment.
Responsibilities
  • As a member of the CMC project teams, act as Regulatory CMC Lead for assigned programs providing strategic guidance to development team(s) on complex regulatory CMC topics.
  • Responsible for leading negotiations with regulators as applicable for initial INDs/CTAs, amendments and future marketing registration applications.
  • Accountable to establish and execute high-quality CMC related submissions including INDs/CTAs or amendments working in collaboration with other stakeholders (ie., research process & analytical development, manufacturing, and other SME’s).
  • Keep abreast of and communicate CMC regulatory requirements to ensure all development activities follow applicable regulations and guidelines.
  • Provide regulatory strategic and tactical support for CMC aspects such as change control & inspection management. Assess proposed manufacturing process changes, provide expertise on raw materials management, DP/DS specifications and release, process characterization & validation, methods development & validation and provide strategic regulatory guidance to enable implementation.
  • Participate in regulatory intelligence activities as they pertain to global CMC regulations and guidance and integrate into program plans.
  • Maintain responsibility for all CMC Regulatory timelines, that also includes managing contract staff and vendors relevant to CMC activities.
  • Build and maintain strong relationships with internal and external stakeholders.

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from its competitors is its strong emphasis on research and development, investing significantly in scientific research to create a proprietary platform for novel therapies. The company generates revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. Vor Biopharma's mission is to transform the treatment landscape for blood cancers by providing innovative solutions that prioritize patient health.

Company Stage

IPO

Total Funding

$147.9M

Headquarters

Cambridge, Massachusetts

Founded

2015

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

0%

2 year growth

32%
Simplify Jobs

Simplify's Take

What believers are saying

  • Vor Bio secured $55.6M funding to support clinical trials with updates expected in 2025.
  • Strategic partnerships, like with Editas Medicine, accelerate product development.
  • FDA's approval of gene-editing therapies may expedite Vor Bio's regulatory pathway.

What critics are saying

  • Increased competition from companies like Editas Medicine could pose challenges.
  • Reliance on successful clinical trials may affect investor confidence if results falter.
  • Financial dependency on private placements may dilute existing shares if mismanaged.

What makes Vor Bio unique

  • Vor Bio's unique approach targets cancer cells while protecting healthy ones.
  • The company focuses on innovative treatments for blood cancers, especially AML.
  • Founded by Dr. Siddhartha Mukherjee, Vor Bio has a team of world-class leaders.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE